News
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump's tariffs taking effect on dozens of countries ...
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
The S&P 500 slipped 0.3 percent after briefly climbing to the edge of its record earlier in the morning. The Dow Jones ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
The Dow and S&P 500 faced a slight dip. However, Nasdaq managed a record high close. Eli Lilly shares fell due to ...
The iPhone maker's shares [rallied for a second day]( ...
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
Emmy Nominees In Comedy Casting Sound Off On Self Tapes, Future Of Their Jobs & Whether Trump's Assault On DEI Should Worry Hollywood ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results